Abstract: A compound represented by formula (I) or a stereoisomer, a tautomer, a crystal form, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof are provided. The compound represented by formula (I) can be used as a kinase inhibitor for preparing a medicament for treating diseases mediated by kinase such as ROS1, NTRK and ALK.

Abstract: A compound useful as a CDK7 kinase inhibitor has a structure shown in formula I The definition of each group and substituent is as described in the description. The compound invention can be used as an inhibitor of cyclin-dependent kinase 7 (CDK7) for the treatment or prevention of proliferative diseases (such as cancers), and in particular for the regulation and treatment of related diseases caused by abnormal activity of cyclin-dependent kinase 7 (CDK7).

Abstract: The present invention relates to the technical field of medicines. Specifically disclosed is a compound as represented by formula I?, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, symbols therein being as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has good pharmacokinetic properties.

Abstract: A kinase inhibitor compound of formula I or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The compound has good inhibitory activity on EGFR and Her2 exon 20 insertion mutation, EGFR exon 19 deletion and L858R point mutation of exon 21.

Abstract: The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmacodynamic and pharmacokinetic performance, and lower toxic side effects.

Abstract: The present invention relates to a compound used as a kinase inhibitor and to the use thereof. The structure of the compound is as shown in formula I. The present compound used as a kinase inhibitor has good inhibitory activity on EGFR and Her2 exon 20 insertion mutations, and has excellent potential to be developed into a drug for treating related diseases.

Abstract: The present invention relates to a compound used as an EGFR kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, and can be used to adjust the kinase activity or treat related diseases, especially non-small cell lung cancer.

Abstract: The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I?), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol therein is as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has better pharmacokinetic properties.

Abstract: Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or deuterate thereof. The compound of formula I can be used as a kinase inhibitor, as a drug for the treatment of ROS1, NTRK, ALK, and other kinase-mediated diseases.

Abstract: The present invention is directed to a [1,3]thiazin-2-amine compound, an application and a pharmaceutical composition, belongs to the field of BACE inhibitors. The [1,3]thiazin-2-amine compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. The compound has a good inhibitory effect on BACE and can be used in preparing a medicament for treating a neurodegenerative disease, such as Alzheimer's disease.

Abstract: A crystal form of a deuterated AZD9291 has an X-ray powder diffraction measured using Cu-K? rays with diffraction peaks at 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2. The crystal form of the deuterated AZD9291 is used in the preparation of medicaments for the treatment of cancer. The crystal form of the deuterated AZD9291 provided by the present invention has stable physical and chemical properties and good metabolic stability, and blood concentrations in vivo and concentrations in the brain thereof are significantly improved, achieving an improved therapeutic effect.

Abstract: A crystal form of a deuterated AZD9291 has an X-ray powder diffraction measured using Cu-K? rays with diffraction peaks at 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2. The crystal form of the deuterated AZD9291 is used in the preparation of medicaments for the treatment of cancer. The crystal form of the deuterated AZD9291 provided by the present invention has stable physical and chemical properties and good metabolic stability, and blood concentrations in vivo and concentrations in the brain thereof are significantly improved, achieving an improved therapeutic effect.

Abstract: The present invention is directed to a [1,3]thiazin-2-amine compound, an application and a pharmaceutical composition, belongs to the field of BACE inhibitors. The [1,3]thiazin-2-amine compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. The compound has a good inhibitory effect on BACE and can be used in preparing a medicament for treating a neurodegenerative disease, such as Alzheimer's disease.

Abstract: Novel bis-quinazoline derivatives as tyrosine kinase inhibitors, synthesis of these compounds, and novel methods for treating tyrosine kinase mediated diseases or disorders using these compounds are disclosed. In particular, the present invention provides tethered quinazoline derivative dimers as inhibitors to the epidermal growth factor receptor (EGFR) tyrosine kinase, pharmaceutical compositions thereof, and their therapeutic uses for treating EGFR kinase-mediated diseases or disorders, such as various cancers, as well as synthetic methods for preparing these novel compounds.

Abstract: Novel bis-quinazoline derivatives as tyrosine kinase inhibitors, synthesis of these compounds, and novel methods for treating tyrosine kinase mediated diseases or disorders using these compounds are disclosed. In particular, the present invention provides tethered quinazoline derivative dimers as inhibitors to the epidermal growth factor receptor (EGFR) tyrosine kinase, pharmaceutical compositions thereof, and their therapeutic uses for treating EGFR kinase-mediated diseases or disorders, such as various cancers, as well as synthetic methods for preparing these novel compounds.